Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Published:2019-05 Issue:5 Volume:20 Page:686-700
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fizazi Karim,Tran NamPhuong,Fein Luis,Matsubara Nobuaki,Rodriguez-Antolin Alfredo,Alekseev Boris Y,Özgüroğlu Mustafa,Ye Dingwei,Feyerabend Susan,Protheroe Andrew,Sulur Giri,Luna Yesenia,Li Susan,Mundle Suneel,Chi Kim N

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease;Finianos;Clin Genitourin Cancer,2018

2. Who dies from prostate cancer?;Patrikidou;Prostate Cancer Prostatic Dis,2014

3. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer;Saad;Urology,2015

4. Prostate cancer: ESMO Consensus Conference Guidelines 2012;Horwich;Ann Oncol,2013

5. Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome;Patrikidou;Urol Oncol,2015

Cited by 578 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic Prostate Cancer: Sequential or Combination Therapy?;Clinical Genitourinary Cancer;2024-12

2. Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis;Clinical Genitourinary Cancer;2024-12

3. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

4. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

5. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-13